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over 70. Mean tumor volume was 5.38 cm3 (0.6-143.3). 
Transient grade 1 or 2 acute toxicities occurred in 8% of all 
cases. No acute toxicities grade > 3 were identified. There 
were no chronic toxicities of any grade. The median follow-
up was 18.6 months (1-65). The 1-year overall survival was 
74.5 % for all patients and 78 % for primary tumors. Local 
control in the irradiated volume is 97 %. 
Conclusions: SBRT is an excellent treatment option for 
elderly patients with good performance status. Our 
encouraging results in terms of survival, local control and 
toxicity are in line with those reported in recent literature 
for younger patients. 
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Purpose/Objective: To evaluate the use of a new algorithm 
for making decisions in elderly early breast cancer patients 
after tumorectomy plus hormone therapy. 
Materials and Methods: This is a prospective preliminary 
study stating June 2014. According to the recommendation of 
the 'Innovation and Best Practices' of the 'IDC-Salud Health 
Group', a new algorithm to manage elderly (> 70 years) 
patients with early breast cancer after conservative surgery 
was designed. This procedure considered the results of the 
CALGB 9343 randomized trial for counseling patients about 
the convenience or not to use radiotherapy. Inclusion criteria 
included patients older than 70 years, early breast cancer (T 
≤ 2cm, clinical N0), ER and PR (+), cerB2 (-), treated by 
tumorectomy. In order to decide whether or not to indicate 
external radiotherapy, the new algorithm included the 
following parameter: life expectation as estimated by a 
specialist in Geriatric Oncology using primarily patients' age 
and the Charlson Comorbidity Index Score. Decision was 
against to indicate radiotherapy in women fulfilling the 
following conditions: life expectation ≤ 5 years, margins > 2 
mm, G1 or G2, no lymphovascular invasion, and to be 
subsidiary to receive hormonotherapy. Those patients with a 
life expectation ≤ 5 years but not fulfilling the rest of the 
others criteria or those with a life expectation > 5 years were 
managed according to both the Canadian nomogram which 
calculates the 10-years local recurrence risk; and the MD 
Anderson nomogram, which calculates the risk of mastectomy 
at both 5 and 10 years in elderly patients. The criteria to 
decide whether or not indicate radiation therapy in these 
patients was based on the calculated reduction in the rate of 
either local recurrence or mastectomy as follows: ≤ 5% 
radiotherapy was not indicated; reduction between 5- 10% 
individualize case, reduction ≥ 10% radiotherapy should be 
always indicated. All patients signed a consent form to 
participate in the study and to assume the risks of local 
recurrence and/or further mastectomy. 
Results: Since June 2014, 73 women with breast cancer were 
seen. Seven of them (9.58%) were older than 70 years. From 
them only three fulfill the inclusion criteria (4.10%) and were 
eligible for the study. They all accepted to be included in the 
study. Data related to decision making are shown in Table 1. 
All of them should have been managed without radiation 
therapy. After a detailed discussion explaining in depth that 
the benefits of the treatment was below 5% and the potential 
risks and side effects, surprisingly all of them opted to 
undergone radiation therapy. 
Conclusions: Patients fulfilling the criteria represent a low 
proportion of breast cancer patients. None of them accepted 
not to have radiation therapy in spite of the small expected 
benefit. This preliminary study suggests that cultural and 
psychological aspects should be considered when counseling 
these patients.  
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Purpose/Objective: To evaluate feasibility and tolerance of 
chemo-radiotherapy (CRT) in elderly patients with locally 
advanced cancers. 
Materials and Methods: Clinical records of patients (pts) 
aged >70 years who underwent CRT between January 2005 
and December 2013 were reviewed. Clinical or pathological 
stage was II-IV. Median Karnofsky performance status (KPS) 
was 85 (range 70-100) and median Charlson Index (CI) was 8.5 
(range 6-11). The most frequent tumour types were: rectal 
cancer (64 pts-46%), anal cancer (22 pts- 15.8%), gastric 
cancer (12 pts- 8.6%), esophageal cancer (10 pts- 7.2%). CRT 
was administered with curative (134 pts, 97.8%) or palliative 
(3 pts, 2.2%) intent. Among the curative treatments, CRT was 
neoadjuvant in 59 pts (44.0%), adjuvant in 36 pts (26.9%) and 
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radical in 42 pts (31.3%). Nineteen pts (13.9%) received 
concurrent CRT after neoadjuvant chemotherapy (CT). 
According to tumour type, 14 pts (10.2%) received platinum 
compounds, 81 (59.1%) fluoropirimidynes, 29 (21.1%) 
mytomicin C and fluororuracil or cisplatin and 5-fluorouracil, 
7 pts (5.1%) received targeted therapy, 5 pts (3.6%) 
temozolomide and in 1 pt (0.8%) mytomicin C. RT was 
delivered with 3D-CRT (112 pts, 81.7%) and IMRT (25 pts, 
18.2%) to a median dose of 57 Gy (range 11-70 Gy) with daily 
fractions of 1.8-2.5 Gy. Compliance to CRT, as treatment 
interruptions or dose modifications, was evaluated. KPS, CI 
and age were also considered, and their correlation with 
acute ≥ grade (G) 2 toxicity (CTCAE v.3 scale) was analyzed. 
Results: Overall, 137 out of 10,251 pts (1.33%), 82 males 
(60%) and 55 females (40%), with median age 74 years (range 
70-90) were analyzed. Scheduled CRT was completed by 132 
pts (96.3%). Five pts (3.6%) definitively stopped CRT: 1 pt 
with gastric cancer had bowel obstruction; 1 pt with 
oesophageal cancer developed brain metastases; 1 pt with 
rectal cancer had G3 gastrointestinal toxicity; 1 pt with 
oesophageal cancer had G2 vomiting; 1 pt with oral cancer 
had G3 mucositis and refused treatment. Overall, 33 pts 
(25%) interrupted CRT: 7 (21.2%) both RT and CT and 26 
(78.8%) only CT. Dose modification of CT was adopted in 16 
pts (11.7%). Twenty-five pts (18.2%) developed haematologi-
cal toxicity, ≥ G2 in 21 cases (84.0%). Gastrointestinal 
toxicity was observed in 55 pts (41.0%) and in 29 of them 
(53.0%) ≥G2. Genitourinary toxicity occurred in 13 pts (9.8%) 
and 8 of them (61.5%) had ≥G2. Mucositis was recorded in 19 
pts (13.9%) and in 29 of them (79.0%) was ≥G2. No statistical 
significant correlation between KPS, CI, age and toxicity was 
found; we observed a trend for correlation between 
mucositis ≥G2 and age (p=0.05). 
Conclusions: In our retrospective study, concurrent CRT for 
elderly pts in different cancer settings seems to be feasible 
with a good toxicity profile. Great attention in prescribing CT 
dose should be paid to limit acute toxicity. 
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Purpose/Objective: Many in-hospital deaths involve 
cardiopulmonary resuscitation (CPR), often when it is unlikely 
to succeed1. Of all patients undergoing CPR in UK hospitals, 
only 22% have their resuscitation status considered prior to 
cardiac arrest1. Patients with cancer have a lower likelihood 
of benefitting from CPR than those without cancer, and the 
extent of cancer spread is inversely proportional to survival 
following CPR2. For oncology inpatients, early documentation 
of escalation and resuscitation status reduces inappropriate 
CPR attempts by a factor of ten and intensive care unit 
referrals by a factor of three3. Nudge theory is concerned 
with the subtle alteration of choice architecture, in order to 
effect positive change without significantly reducing the 
options available to decision-makers4. This quality 
improvement project attempted to use a nudge theory-based 
intervention in order to increase the rates of CPR and 
escalation decision-making for oncology inpatients.  
Materials and Methods: Rates of resuscitation and escalation 
decision-making were recorded weekly from a representative 
selection of five sets of patient medical notes on an oncology 
inpatient ward from December 2013 to March 2014. In 
January 2014 the medical team’s ward list of patients was 
subtly altered: the column labelled ‘Blood results’ was 
changed to ‘CPR/ceiling’ (i.e. ceiling of treatment). The 
rates of documented decision-making were recorded weekly 
following this nudge intervention to assess its impact.  
Results: Prior to the nudge intervention, rates of 
resuscitation and escalation decision-making ranged from 
zero to twenty percent. Following the nudge intervention, 
rates of documented decision-making steadily increased, 
until between eighty and one hundred percent of patients on 
the oncology ward had documented decisions about CPR and 
escalation.  
 
 
Conclusions: The nudge intervention of changing the medical 
ward list, which represented a very small outlay in terms of 
cost and effort, led to a large increase in resuscitation and 
escalation decision-making for oncology inpatients. We 
believe that this dramatic effect can be replicated in other 
areas of oncology. Given how cost effective such 
interventions tend to be, we recommend further research 
into novel applications of Nudge Theory within oncology 
practice.  
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